Oliwia Koszła

Ms. Oliwia Koszła

Medical Univeristy of Lublin
orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 August 2024 in Cell Communication and Signaling
Verified
Journal Article
Open access
PDF file
OKOliwia Koszła
Oliwia Koszła
PSPrzemysław Sołek
Przemysław Sołek
The primary challenge in today’s world of neuroscience is the search for new therapeutic possibilities for neurodegenerative disease. Central to these disorders lies among other factors, the aberrant folding, aggregation, and accumulation of proteins, resulting in the formation of toxic entities that contribute to neuronal degeneration. This review concentrates on the key proteins such as β-amyloid (Aβ), tau, and α-synuclein, elucidating the intricate molecular events underlying their misfolding and aggregation. We critically evaluate the molecular mechanisms governing the elimination of misfolded proteins, shedding light on potential therapeutic strategies. We specifically examine pathways such as the endoplasmic reticulum (ER) and unfolded protein response (UPR), chaperones, chaperone-mediated autophagy (CMA), and the intersecting signaling of Keap1-Nrf2-ARE, along with autophagy connected through p62. Above all, we emphasize the significance of these pathways as protein quality control mechanisms, encompassing interventions targeting protein aggregation, regulation of post-translational modifications, and enhancement of molecular chaperones and clearance. Additionally, we focus on current therapeutic possibilities and new, multi-target approaches. In conclusion, this review systematically consolidates insights into emerging therapeutic strategies predicated on protein aggregates clearance.

11 September 2020 in Expert Opinion on Drug Discovery
Verified
Journal Article
Closed access
PSPiotr Stępnicki
Piotr Stępnicki
MKMagda Kondej
Magda Kondej
OKOliwia Koszła
Oliwia Koszła
JŻJustyna Żuk
Justyna Żuk
Agnieszka KaczorAgnieszka Kaczor
Agnieszka Kaczor
Schizophrenia is a complex psychiatric disease (or a conglomeration of disorders) manifesting with positive, negative and cognitive symptoms. The pathophysiology of schizophrenia is not completely ...

16 June 2021 in Biomolecules
Verified
Journal Article
Open access
PDF file
OKOliwia Koszła
Oliwia Koszła
PSPiotr Stępnicki
Piotr Stępnicki
AZAgata Zieba
Agata Zieba
AGAngelika Grudzińska
Angelika Grudzińska
Dariusz MatosiukDariusz Matosiuk
Dariusz Matosiuk
Agnieszka KaczorAgnieszka Kaczor
Agnieszka Kaczor
Parkinson’s disease is a progressive neurodegenerative disorder characterized by the death of nerve cells in the substantia nigra of the brain. The treatment options for this disease are very limited as currently the treatment is mainly symptomatic, and the available drugs are not able to completely stop the progression of the disease but only to slow it down. There is still a need to search for new compounds with the most optimal pharmacological profile that would stop the rapidly progressing disease. An increasing understanding of Parkinson’s pathogenesis and the discovery of new molecular targets pave the way to develop new therapeutic agents. The use and selection of appropriate cell and animal models that better reflect pathogenic changes in the brain is a key aspect of the research. In addition, computer-assisted drug design methods are a promising approach to developing effective compounds with potential therapeutic effects. In light of the above, in this review, we present current approaches for developing new drugs for Parkinson’s disease.

5 July 2019 in Apoptosis
Verified
Journal Article
Open access
PDF file
PSPrzemyslaw Solek
Przemyslaw Solek
OKOliwia Koszła
Oliwia Koszła
JMJennifer Mytych
Jennifer Mytych
JBJoanna Badura
Joanna Badura
ZCZaneta Chelminiak
Zaneta Chelminiak
MKMarek Koziorowski
Marek Koziorowski
Depression is a serious medical condition, typically treated by antidepressants. Conventional monotherapy can be effective only in 60–80% of patients, thus modern psychiatry deals with the challenge of new methods development. At the same moment, interactions between antidepressants and the occurrence of potential side effects raise serious concerns, which are even more exacerbated by the lack of relevant data on exact molecular mechanisms. Therefore, the aims of the study were to provide up-to-date information on the relative mechanisms of action of single antidepressants and their combinations. In this study, we evaluated the effect of single and combined antidepressants administration on mouse hippocampal neurons after 48 and 96 h in terms of cellular and biochemical features in vitro. We show for the first time that co-treatment with amitriptyline/imipramine + fluoxetine initiates in cells adaptation mechanisms which allow cells to adjust to stress and finally exerts less toxic events than in cells treated with single antidepressants. Antidepressants treatment induces in neuronal cells oxidative and nitrosative stress, which leads to micronuclei and double-strand DNA brakes formation. At this point, two different mechanistic events are initiated in cells treated with single and combined antidepressants. Single antidepressants (amitriptyline, imipramine or fluoxetine) activate cell cycle arrest resulting in proliferation inhibition. On the other hand, treatment with combined antidepressants (amitriptyline/imipramine + fluoxetine) initiates p16-dependent cell cycle arrest, overexpression of telomere maintenance proteins and finally restoration of proliferation. In conclusion, our findings may pave the way to better understanding of the stress-related effects on neurons associated with mono- and combined therapy with antidepressants.

1 October 2019 in European Journal of Medicinal Chemistry
Verified
Journal Article
Closed access
MKMagda Kondej
Magda Kondej
Tomasz WróbelTomasz Wróbel
Tomasz Wróbel
ASAndrea G. Silva
Andrea G. Silva
PSPiotr Stępnicki
Piotr Stępnicki
OKOliwia Koszła
Oliwia Koszła
Agnieszka KaczorAgnieszka Kaczor
Agnieszka Kaczor

19 January 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
OKOliwia Koszła
Oliwia Koszła
KTKatarzyna Targowska-Duda
Katarzyna Targowska-Duda
EKEwa Kędzierska
Ewa Kędzierska
Agnieszka KaczorAgnieszka Kaczor
Agnieszka Kaczor
Schizophrenia (SZ) is a complex psychiatric disorder characterized by positive, negative, and cognitive symptoms, and is not satisfactorily treated by current antipsychotics. Progress in understanding the basic pathomechanism of the disease has been hampered by the lack of appropriate models. In order to develop modern drugs against SZ, efficient methods to study them in in vitro and in vivo models of this disease are required. In this review a short presentation of current hypotheses and concepts of SZ is followed by a description of current progress in the field of SZ experimental models. A critical discussion of advantages and limitations of in vitro models and pharmacological, genetic, and neurodevelopmental in vivo models for positive, negative, and cognitive symptoms of the disease is provided. In particular, this review concerns the important issue of how cellular and animal systems can help to meet the challenges of modeling the disease, which fully manifests only in humans, as experimental studies of SZ in humans are limited. Next, it is emphasized that novel clinical candidates should be evaluated in animal models for treatment-resistant SZ. In conclusion, the plurality of available in vitro and in vivo models is a consequence of the complex nature of SZ, and there are extensive possibilities for their integration. Future development of more efficient antipsychotics reflecting the pleiotropy of symptoms in SZ requires the incorporation of various models into one uniting model of the multifactorial disorder and use of this model for the evaluation of new drugs.